ASH 2023 Multiple Myeloma

CE / CME

Conference to Clinic: Expert Analysis of the Top Multiple Myeloma Abstracts From the 2023 ASH Annual Meeting

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 07, 2024

Expiration: March 06, 2025

Sagar Lonial
Sagar Lonial, MD, FACP

Activity

Progress
1 2
Course Completed

References

  1. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized study of daratumumab + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: Primary results of the PERSEUS trial. Presented at: 65th Annual Meeting of the American Society of Hematology December 9-12, 2023. Abstract LBA-1.
  2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301-313.
  3. Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825-e837.
  4. van de Donk NW, Gorgun G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012;4:253-268.
  5. Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497-503.
  6. Geraldes C, Neves M, Chacim S, da Costa FL. Practical considerations for the daratumumab management in portuguese routine clinical practice: Recommendations from an expert panel of hematologists. Front Oncol. 2021;11:817762.
  7. Joseph NS, Kaufman JL, Dicamillo S, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Presented at: 65th Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 647.
  8. Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Presented at: 65th Annual Meeting of the American Society of Hematology December 9-12, 2023. Abstract 4.
  9. Siegel DS. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013;4:354-365.
  10. Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study. Presented at: 65th Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 1010.
  11. Jagannath S, Richter J, Dhodapkar MV, et al. Patterns of response to 200 mg linvoseltamab in patients with relapsed/refractor multiple myeloma: Longer follow-up of the LINKER-MM1 study. Presented at: 65th Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 4746.
  12. Swan D, Murphy P, Glavey S, Quinn J. Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety. Cancers (Basel). 2023;15.
  13. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495-505.
  14. Bahlis NJ, Quach H, Baz R, et al. Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: Updated analyses of minimal residual disease negativity in phase 1/2 study. Presented at: 65th Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 338.
  15. Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1600-1609.
  16. Ehsan H, Wahab A, Shah Z, et al. Role of venetoclax in the treatment of relapsed and refractory multiple myeloma. J Hematol. 2021;10:89-97.
  17. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630-1642.
  18. Landgren O, Chari A, Cohen YC, et al. Efficacy and safety of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): Final analysis of the phase 2 Centaurus study. Presented at: 65th Annual Meeting of the American Society of Hematology; December 9-12, 2023. Abstract 210.